Head-to-head · WeighScore
AskRx vs Eve
The verdict
Eve takes it — 66/100 to 55.8/100.
Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | AskRx | Eve |
|---|---|---|
| WeighScore | 55.8/100 | 66/100 |
| Grade | C | C |
| Scorecard rank | #430 | #212 |
| Semaglutide | $349/mo (all doses, brand-name) | $195/mo (compounded) |
| Tirzepatide | $299/mo (2.5 mg dose, brand-name) | $195/mo (compounded) |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #430 · C
Strengths
- Prescribes only FDA-approved brand-name GLP-1s, no compounded drugs
- LegitScript approved and HIPAA compliant
- Board-certified physicians trained in obesity medicine
- Transparent dose-based pricing published on site
- Available in all 50 states
Where it loses points
- Cash-pay model; medication cost billed separately by the pharmacy
- Does not dispense medication itself, so fulfillment depends on third-party pharmacies
- No compounded lower-cost alternative offered
- Specific list of supported states is not published
Graded #212 · C
Strengths
- Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
- Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
- LegitScript Certified with a verifiable ID
- Publishes the FDA compounded-medication disclaimer
- Oral sublingual semaglutide offered alongside injectable
Where it loses points
- Full states-served list not disclosed publicly
- 503A pharmacy partner not named, and 503A vs 503B status not specified
- Named medical director / clinical leadership not disclosed
- Corporate legal entity not disclosed
- Governing law / arbitration venue not stated
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.